14 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in May 2044. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
May 2044
Next term end
8
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 1 of the currently held patents qualifies as notable.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 17, 2027.
Recent changes
- 2 of the patents on this record were granted since Aug 21, 2026
What they patent
The largest of its 8 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Injectable Formulations for Treatment of Inflammatory Bowel Disease | 4 in force | to May 2044 |
| Albumin Binding Proteins and Methods of Use | 3 in force | to Apr 2045 |
| TL1A Binding Proteins and Methods of Use | 2 in force | to Aug 2044 |
| PD-1 Binding Proteins, VEGF and PD-1 Bispecific Binding Proteins, Compositions, and Methods of Use | 1 in force | to Sep 2045 |
| IL-17 Binding Proteins, Compositions, and Methods of Use Thereof | 1 in force | to Sep 2045 |
| IL-23 Antibody Compositions and Methods of Use | 1 in force | to Feb 2045 |
| IL-23 Binding Protein Compositions and Methods of Use | 1 in force | to Feb 2045 |
| ALPHA4BETA7 Integrin Binding Proteins and Methods of Use | 1 in force | to Aug 2044 |
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,304,956 | Dosing Regimen for Treating Inflammatory Bowel Disease In force · High confidence | In force | High confidence | |
| US 12,404,334 | Methods of Treating Gastrointestinal Inflammatory Disease In force · High confidence | In force | High confidence | |
| US 12,703,749 | Method of Treating Inflammatory Bowel Disease In force · High confidence | In force | High confidence | |
| US 12,760,108 | Injectable Formulations for Treatment of Inflammatory Bowel Disease In force · Medium confidence | In force | Medium confidence | |
| US 12,466,890 | TL1A Binding Proteins and Methods of Use In force · High confidence | In force | High confidence | |
| US 12,509,523 | TL1A Binding Proteins and Methods of Use In force · Medium confidence | In force | Medium confidence | |
| US 12,606,627 | ALPHA4BETA7 Integrin Binding Proteins and Methods of Use In force · Medium confidence | In force | Medium confidence | |
| US 12,522,655 | IL-23 Antibody Compositions and Methods of Use In force · Medium confidence | In force | Medium confidence | |
| US 12,655,208 | IL-23 Binding Protein Compositions and Methods of Use In force · Medium confidence | In force | Medium confidence | |
| US 12,459,994 | Albumin Binding Proteins and Methods of Use In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 14: 18 applications pending · 1 application abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 terminal disclaimer is on file with no resolved reference. No cap is applied and none is guessed
10 computed term dates come from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.